The ECHS Central Organisation is located at Delhi and functions under the Chief of Staff Committee (COSC) through AG and DGDC&W in Army HQ. The Central organisation is headed by Managing Director, ECHS, a serving Major General. There are 28 Regional Centres ECHS and 426 ECHS Polyclinics. ECHS is also an attached office of Dept of Ex-Servivemen Welfare (DoESW), Ministry of Defence (MoD) as are Directorate General Resettlement(DGR) and Kendriya Sainik Board (KSB).

Post : Pharmacist

CSIR-Indian Institute of Integrative Medicine (CSIR-IIIM), Jammu, is a premier Institute working under the aegis of Council of Scientific & Industrial Research (CSIR), an autonomous body under the Department of Scientific & Industrial Research (DSIR), Ministry of Science & Technology, Government of India. 

Post : Project Associate-I [One Positions]

The PGIMER owes its inception to the vision of late Sardar Partap Singh Kairon, the then Chief Minister of Punjab and the distinguished medical educationists of the then combined state of Punjab, supported by the first Prime Minister of India Pt. Jawahar Lal Nehru who considered the institutions of scientific knowledge as temples of learning and the places of pilgrimage. The institute started in 1962 and Pt Jawahar Lal Nehru inaugurated the hospital now named “Nehru Hospital” on 7th July 1963. The Institute was originally under the Government of undivided Punjab.

An international team of researchers has identified a previously unknown genetic cause of severe Crohn's disease in children, a breakthrough that could improve diagnosis and pave the way for more targeted treatments for inflammatory bowel disease (IBD). The findings were published in the journal Gastroenterology.

The U.S. Food and Drug Administration (FDA) has approved a new indication for Pfizer's IBRANCE (palbociclib), allowing its use in combination with trastuzumab, with or without pertuzumab, and endocrine therapy as maintenance treatment for adults with hormone receptor-positive (HR+), HER2-positive (HER2+) locally advanced or metastatic breast cancer following induction therapy. The approval marks a significant expansion for the widely used CDK4/6 inhibitor.

The World Health Organization (WHO) has taken another significant step toward strengthening the quality, safety, and regulation of herbal medicines by advancing the development of an International Herbal Pharmacopoeia (IHP). During the 5th WHO Expert Meeting held in Hong Kong SAR (China) from 16–18 June 2026, experts from all six WHO regions met to accelerate the creation of globally harmonized standards for herbal medicines.

The European Union has awarded 15 million euro under its Horizon Europe research and innovation program to launch REPhRAME, an ambitious international project aimed at developing a new treatment strategy for recurrent urinary tract infections (UTIs). Coordinated by Universitätsmedizin Frankfurt under the leadership of Prof. Dr. Maria J.G.T. Vehreschild, the five-year project will evaluate phage therapy as a potential alternative to antibiotics in patients suffering from recurrent bacterial infections.